Abner Herrman & Brock’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.5M Buy
27,138
+300
+1% +$307K 3.09% 9
2026
Q1
$24.7M Buy
26,838
+65
+0.2% +$65.9K 2.73% 13
2025
Q4
$28.8M Sell
26,773
-1,027
-4% -$982K 2.94% 9
2025
Q3
$21.2M Buy
27,800
+152
+0.5% +$113K 2.19% 18
2025
Q2
$21.6M Buy
27,648
+314
+1% +$244K 2.41% 15
2025
Q1
$22.6M Buy
27,334
+477
+2% +$397K 2.88% 10
2024
Q4
$20.7M Buy
26,857
+349
+1% +$289K 2.58% 14
2024
Q3
$23.5M Buy
26,508
+103
+0.4% +$92.6K 2.83% 11
2024
Q2
$23.9M Buy
26,405
+33
+0.1% +$26.4K 3.03% 7
2024
Q1
$20.5M Buy
26,372
+373
+1% +$265K 2.56% 13
2023
Q4
$15.2M Buy
25,999
+17,889
+221% +$10.4M 2.13% 26
2023
Q3
$4.36M Buy
8,110
+8
+0.1% +$4.12K 0.67% 40
2023
Q2
$3.8M Buy
8,102
+72
+0.9% +$30.2K 0.56% 41
2023
Q1
$2.76M Sell
8,030
-3,733
-32% -$1.26M 0.42% 48
2022
Q4
$4.3M Buy
11,763
+3,753
+47% +$1.33M 0.66% 39
2022
Q3
$2.59M Buy
8,010
+6,894
+618% +$2.18M 0.47% 43
2022
Q2
$362K Buy
+1,116
New +$335K 0.06% 69
2016
Q4
Sell
-15,143
Closed -$1.22M 123
2016
Q3
$1.22M Buy
+15,143
New +$1.21M 0.28% 62

Other funds holding LLY

Abner Herrman & Brock's LLY Position: Q2 2026 in Review

Abner Herrman & Brock increased its Eli Lilly (LLY) stake by 1.1% in Q2 2026, buying an estimated $307K and bringing the position to 27,138 shares worth $32.5M. The position accounts for 3.09% of the portfolio, ranked #9.

Abner Herrman & Brock first reported a position in LLY in Q3 2016 and has held it in 18 quarters since. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Abner Herrman & Brock held 27,138 shares of Eli Lilly worth $32.5M as of Q2 2026.
  • Abner Herrman & Brock bought 300 Eli Lilly shares in Q2 2026, an estimated $307K.
  • Eli Lilly made up 3.09% of Abner Herrman & Brock's portfolio in Q2 2026, its #9 holding.
  • Abner Herrman & Brock first reported a position in Eli Lilly in Q3 2016 and has held it in 18 quarters since.
  • 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Abner Herrman & Brock's 13F filing for Q2 2026, filed 8 Jul 2026.